Opt Health

About Opt Health

Opt Health launched in 2019 as a men’s health optimization platform, positioning itself as a concierge-level telehealth service for men seeking to improve energy, body composition, and overall metabolic health. The company offers compounded semaglutide as part of its weight management program, with monthly costs ranging from $199 to $399. Opt Health’s approach emphasizes personalized treatment plans built on comprehensive diagnostics, setting it apart from providers that take a more transactional approach to GLP-1 prescribing.

Trust data for Opt Health is limited. The company has no Trustpilot reviews on its Trustpilot page at the time of this review, which means we cannot assess public patient sentiment through that channel. The C+ BBB rating is middling — not alarming, but not a strong endorsement either. The absence of a robust public review profile is a gap that prospective patients should factor into their decision, particularly given that more established telehealth providers in this space typically offer thousands of verified reviews to draw on.

Where Opt Health excels is in its high-support clinical model. The platform includes lab testing as a standard part of its program, and treatment plans are built around individual metabolic profiles rather than standardized protocols. Patients work with dedicated providers who monitor progress, adjust dosing, and coordinate care across multiple health domains. For men managing weight alongside testosterone optimization, thyroid health, or cardiovascular risk factors, this integrated approach can produce better outcomes than siloed treatment.

The personalized treatment philosophy extends to Opt Health’s patient experience. The platform markets itself as a premium service, and patients report receiving more one-on-one provider time than typical telehealth encounters offer. This concierge-style model justifies the mid-to-upper pricing tier for patients who value relationship-based care over cost minimization. However, the premium positioning also means Opt Health is not competitive on price alone — patients primarily motivated by affordability will find better options elsewhere.

The limitation of offering only compounded semaglutide narrows Opt Health’s appeal. Patients interested in tirzepatide, liraglutide, or brand-name GLP-1 formulations will need to look elsewhere. Combined with the lack of public reviews, Opt Health is a provider we respect for its clinical philosophy but cannot fully validate through independent patient data. It earns points for care quality and loses them for transparency and medication breadth.

Opt Health GLP-1 Medications

At a Glance